Biblio

Author Title [ Type

] Year

Filters: Author is Brümmendorf, Tim H [Clear All Filters]

Journal Article

Isfort S, Amsberg GKeller-V, Schafhausen P, Koschmieder S, Brümmendorf TH. Bosutinib: a novel second-generation tyrosine kinase inhibitor. Recent Results Cancer Res. 2014;201:81-97.

Han L, Schubert C, Köhler J, Schemionek M, Isfort S, Brümmendorf TH, Koschmieder S, Chatain N. Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion. J Hematol Oncol. 2016;9(1):45.

Vieri M, Tharmapalan V, Kalmer M, Baumeister J, Nikolić M, Schnitker M, Kirschner M, Flosdorf N, de Toledo MAS, Zenke M, et al. Cellular aging is accelerated in the malignant clone of myeloproliferative neoplasms. Blood Cancer J. 2023;13(1):164.

Kricheldorf K, Döhner K, Stegelmann F, Jost PJ, Lang F, Radsak M, Hansen R, Heuer V, Röhrig R, Brümmendorf TH, et al. Challenges of patients with myeloproliferative neoplasms (MPN) in times of COVID: First results from a patient survey by the German Study Group for MPN. Leuk Res. 2021;110:106646.

de Vries ISNaarmann, Sackmann Y, Klein F, Ostareck-Lederer A, Ostareck DH, Jost E, Ehninger G, Brümmendorf TH, Marx G, Röllig C, et al. Characterization of acute myeloid leukemia with del(9q) - Impact of the genes in the minimally deleted region. Leuk Res. 2018;76:15-23.

Stegelmann F, Teichmann LL, Heidel FH, Crodel CC, Ernst T, Kreil S, Reiter A, Otten S, Schauer S, Körber R-M, et al. Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN). Leukemia. 2023.

Boettcher S, C Wilk M, Singer J, Beier F, Burcklen E, Beisel C, Ferreira MSVentura, Gourri E, Gassner C, Frey BM, et al. Clonal hematopoiesis in donors and long-term survivors of related allogeneic hematopoietic stem cell transplantation. Blood. 2020.

Römer T, Vokuhl C, Staatz G, Mottaghy FM, Christiansen H, Eble MJ, Timmermann B, Klussmann JPeter, Elbracht M, Calaminus G, et al. Combination of nivolumab with standard induction chemotherapy in children and adults with EBV-positive nasopharyngeal carcinoma : Protocol of a prospective multicenter phase 2 trial. HNO. 2024.

Maletzke S, Salimi A, Vieri M, Schroeder KMarlen, Schemionek M, Masouleh BKharabi, Brümmendorf TH, Koschmieder S, Appelmann I. Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia. PLoS One. 2022;17(10):e0268352.

Boehnke J, Atakhanov S, Toledo MAS, Schüler HM, Sontag S, Chatain N, Koschmieder S, Brümmendorf TH, Kramann R, Zenke M. CRISPR/Cas9 mediated CXCL4 knockout in human iPS cells of polycythemia vera patient with JAK2 V617F mutation. Stem Cell Res. 2021;55:102490.

Rolles B, Meyer R, Begemann M, Elbracht M, Jost E, Stelljes M, Kurth I, Brümmendorf TH, Silling G. DDX41 germline variants causing donor cell leukemia indicate a need for further genetic workup in the context of hematopoietic stem cell transplantation. Blood Cancer J. 2023;13(1):73.

Baumeister J, Maié T, Chatain N, Gan L, Weinbergerova B, de Toledo MAS, Eschweiler J, Maurer A, Mayer J, Kubesova B, et al. Early and late stage MPN patients show distinct gene expression profiles in CD34 cells. Ann Hematol. 2021.

Iberl S, Meyer A-L, Müller G, Peters S, Johannesen S, Kobor I, Beier F, Brümmendorf TH, Hart C, Schelker R, et al. Effects of continuous high-dose G-CSF administration on hematopoietic stem cell mobilization and telomere length in patients with amyotrophic lateral sclerosis - a pilot study. Cytokine. 2019;120:192-201.

Koschmieder S, Isfort S, Wolf D, Heidel FH, Hochhaus A, Schafhausen P, Griesshammer M, Wolleschak D, Platzbecker U, Döhner K, et al. Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group. Ann Hematol. 2022.

Mahon F-X, Pfirrmann M, Dulucq S, Hochhaus A, Panayiotidis P, Almeida A, Mayer J, Hjorth-Hansen H, Janssen JJWM, Mustjoki S, et al. European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission. J Clin Oncol. 2024:JCO2301647.

Heuser C, Schneider JNora, Heier L, Ernstmann N, Nakata H, Petermann-Meyer A, Bremen R, Karger A, Icks A, Brümmendorf TH, et al. Family resilience of families with parental cancer and minor children: a qualitative analysis. Front Psychol. 2023;14:1251049.

Koschmieder S, Jost E, Cornelissen C, Müller T, Schulze-Hagen M, Bickenbach J, Marx G, Kleines M, Marx N, Brümmendorf TH, et al. Favorable COVID-19 course despite significant comorbidities in a ruxolitinib-treated patient with primary myelofibrosis. Eur J Haematol. 2020.

Crysandt M, Brings K, Beier F, Thiede C, Brümmendorf TH, Jost E. Germline predisposition to myeloid malignancies appearing in adulthood. Expert Rev Hematol. 2018.

Leimkühler NB, Gleitz HFE, Ronghui L, Snoeren IAM, Fuchs SNR, Nagai JS, Banjanin B, Lam KH, Vogl T, Kuppe C, et al. Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis. Cell Stem Cell. 2020.

Crysandt M, Kramer M, Ehninger G, Bornhäuser M, Berdel WE, Serve H, Röllig C, Kaifie A, Jost E, Brümmendorf TH, et al. A high BMI is a risk factor in younger patients with de novo acute myelogenous leukemia. Eur J Haematol. 2015.

Tometten M, Kirschner M, Meyer R, Begemann M, Halfmeyer I, Vieri M, Kricheldorf K, Maurer A, Platzbecker U, Radsak M, et al. Identification of Adult Patients With Classical Dyskeratosis Congenita or Cryptic Telomere Biology Disorder by Telomere Length Screening Using Age-modified Criteria. Hemasphere. 2023;7(5):e874.

Andert A, Alizai HP, Ulmer TFlorian, Heidenhain C, Ziegler P, Brümmendorf TH, Neumann UPeter, Beier F, Klink CD. Influence of Telomere Length in Hepatocytes on Liver Regeneration after Partial Hepatectomy in Rats. Eur Surg Res. 2018;59(1-2):83-90.

Rahn K, Abdallah AT, Gan L, Herbrich S, Sonntag R, Benitez O, Malaney P, Zhang X, Rodriguez AG, Brottem J, et al. Insight into the mechanism of AML del(9q) progression: hnRNP K targets the myeloid master regulators CEBPA (C/EBPα) and SPI1 (PU.1). Biochim Biophys Acta Gene Regul Mech. 2023:195004.

Diener Y, Walenda T, Jost E, Brümmendorf TH, Bosio A, Wagner W, Bissels U. MicroRNA expression profiles of serum from patients before and after chemotherapy. Genom Data. 2015;6:125-7.

Walenda T, Diener Y, Jost E, Morin-Kensicki E, Goecke TW, Bosio A, Rath B, Brümmendorf TH, Bissels U, Wagner W. MicroRNAs and Metabolites in Serum Change after Chemotherapy: Impact on Hematopoietic Stem and Progenitor Cells. PLoS One. 2015;10(5):e0128231.

Pages